Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Subscribe To Our Newsletter & Stay Updated